Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119846
Chunk: 221

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 221
---
. market. There is a good degree of overlap between the current Scilex sales force HCP targets and HCPs who prescribe medications for acute migraine, allowing for efficient dual 
 promotion of ELYXYB and ZTlido. The principal elements of the ELYXYB strategy are the following:                                                                                                                                            |

| • |     | Educate the market on the need for and value of a novel and differentiated option for the treatment of acute                                                                                                  
 migraine, where a high degree of unmet medical need already exists. We will leverage our in-person sales field forces, medical affairs teams, and omni-channel HCP engagement campaigns to drive awareness of 
 ELYXYB features and benefits.                                                                                                                                                                                 |

| • |     | Broaden access to ELYXYB. Our managed healthcare account executives will negotiate contracts with key payer and 
 pharmacy stakeholders to achieve uptake to key formularies.                                                     |

| • |     | Commercialize and successfully continue launch of                                                                                                                                                                                                                                                                                             
 GLOPERBA® for gout in the U.S. We will utilize our current commercial infrastructure comprised of our sales, marketing, and managed health care functions to promote GLOPERBA® for gout to approximately 3,000 HCPs in the U.S. market. We anticipate a good degree of overlap between the current HCPs that we target and HCPs who prescribe |

139

| colchicine for gout, allowing for efficient dual promotion of GLOPERBA and ZTlido. The principal elements of the GLOPERBA strategy are as follows: |

| • |     | Educate the market on the need for and value of simplified and precise colchicine dose adjustments to allow                                                                                                                                       
 individualized, patient-by-patient therapy. Scilex will leverage its in-person sales forces, medical affairs teams, and                                                                                                                           
 omni-channel HCP engagement campaigns to drive awareness of GLOPERBA’s features and benefits. In addition, target providers, rheumatologists and primary care physicians treating various comorbidities, will be provided with tools to help them 
 identify and prescribe GLOPERBA to appropriate patients.                                                                                                                                                                                          |

| • |     | Increase access to GLOPERBA for subsets of patients in prophylactic treatment of gout, specifically those with                                                                   
 comorbidities and GI intolerance. Our managed healthcare account executives will negotiate contracts with key payer and pharmacy customers to achieve uptake of key formularies. |

| • |     | Develop